Captiva is a spinal fixation system intended for specific surgical applications. The device is designed for posterior, non-cervical pedicle fixation to provide immobilization and stabilization of spinal segments when used as an adjunct to fusion surgery.

Its intended therapeutic use is to aid in the management of acute and chronic instabilities or deformities in the thoracic, lumbar, and sacral spine. This may include conditions such as degenerative disc disease (DDD), spondylolisthesis, trauma, spinal stenosis, tumor, pseudoarthrosis, or failed previous fusion. The device's primary function is supportive stabilization to assist the fusion process and may help manage associated pain and structural issues.

“Understanding the precise indications helps patients and providers make informed treatment decisions.”

---

Quick Fact: Support for Instability and Degenerative Pain Management

Official Eligibility and Non-Eligibility for Captiva (Albendazole)

Eligibility Status	Applicable Population	Constraint Details
Contraindicated	Pregnancy or Hypersensitivity	Prohibited in pregnant women and those with known allergy to benzimidazole drugs or formulation components. Females of reproductive potential require a negative pregnancy test and effective contraception [FDA, SmPC].
Use Allowed	Adults and Children	Generally approved for use in individuals over two years of age for short-term courses of therapy [SmPC].
Restricted Use	Hepatic Dysfunction	Use requires caution and close monitoring of liver enzyme levels and blood counts due to increased risk of hepatotoxicity and bone marrow suppression [FDA, SmPC].
Not Recommended	Lactation	Use is not recommended while breastfeeding. For single-dose regimens, discontinuation of breastfeeding for a short period is typically advised [SmPC].
Monitoring Required	Hematological Disorders	Patients with pre-existing bone marrow suppression or blood disorders must undergo mandatory monitoring of blood counts at required intervals [FDA].
Pre-Treatment Rule	Retinal Cysticercosis	An ophthalmologic examination is required before initiating treatment for neurocysticercosis to rule out retinal lesions [FDA].

Interaction Scope

Medicinal product categories with documented interactions: Anticonvulsants, Anthelmintics, H2-receptor antagonists, Corticosteroids, and Myelosuppressive agents.

Specific interacting medicines (if explicitly listed): Praziquantel, Dexamethasone, and Cimetidine are documented to increase exposure, while Phenytoin, Fosphenytoin, Phenobarbital, and Carbamazepine may reduce active metabolite levels. Monitoring is recommended for Theophylline.

Mechanistic basis of interactions (only if stated in label):

• Pharmacokinetic Exposure Modification: Co-administration with certain drugs formally increases the plasma concentration (Cmax) and systemic exposure (AUC) of the active metabolite, Albendazole Sulfoxide.
• CYP-Mediated Interaction (Induction): Albendazole is documented to induce cytochrome P450 1A enzyme activity, potentially affecting the clearance of co-administered substrates.

Interaction-related restrictions: Use is restricted in individuals with known hypersensitivity to the benzimidazole class of compounds. Caution is advised regarding the risk of additive myelosuppression when co-administering with other myelosuppressive agents. Ingestion with a fatty meal is required to significantly enhance oral absorption and bioavailability, and Grapefruit juice is documented to increase active metabolite levels.

Population-specific interaction notes (if applicable): Patients with underlying liver disease or those with hepatic echinococcosis are noted to be at increased risk for bone marrow suppression when treatment is initiated.

Resulting Interaction Structure

Official interaction statements: Co-administration with Praziquantel or Dexamethasone increases the systemic exposure of the active metabolite. The combination with Cimetidine increases the active metabolite concentration in bile and cystic fluid. Certain anticonvulsants may reduce the plasma concentrations of the active metabolite through enhanced metabolism. The drug is classified as an inducer of cytochrome P450 1A.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents primarily define the interaction structure based on pharmacokinetic exposure modification, where the plasma concentration of the active metabolite is formally altered by specific co-administered drugs. A significant constraint involves the mandated drug–food interaction requiring administration with a high-fat meal to ensure adequate systemic absorption. Furthermore, the profile includes cautions on pharmacodynamic additive toxicity when combined with other myelosuppressive agents.

Molecular Targeting of Parasitic Microtubules

The action of Captiva (Albendazole) is initiated by its active metabolite, which acts by inhibiting the parasitic worm’s mathbfbeta-tubulin subunit. By binding to this crucial molecular component, the drug prevents tubulin from polymerizing into microtubules. This mechanism fundamentally targets the structural integrity of the parasite's cells, particularly those responsible for nutrient absorption, resulting in their cellular collapse.

Energy Deprivation and Systemic Metabolic Cascade

The loss of microtubules directly and severely impairs the parasite’s ability to utilize its main fuel source, glucose. This pathway interference leads to metabolic compromise: the failure to absorb glucose depletes the parasite's glycogen reserves and reduces the production of ATP (energy). This sustained energy deprivation and structural failure results in the progressive cessation of motility and loss of organism viability.

Mechanistic Selectivity

The drug's mechanism benefits from high selectivity, which is achieved by its metabolite possessing a much stronger binding affinity for the helminth's beta-tubulin than for the host (human) cell's equivalent structure. This inherent molecular difference ensures the primary destructive effect is confined to the parasitic target.

How to Use Captiva (Albendazole)

The administration of Captiva involves specific protocols regarding the correct route, dosing regimen, and timing conditions required for its use. The medicine is delivered exclusively via the oral route, available as both an oral tablet and an oral suspension.

Dosing and Frequency Patterns

The standard dosing regimen is dependent on the type of parasitic infection being addressed (systemic vs. intestinal) and the patient's body weight. For systemic infections, dosing is twice daily (BID), with patients weighing 60 kg or more typically receiving 400 mg twice daily. For those weighing less than 60 kg, the total daily dose is calculated as 15 mg/kg, divided into two daily administrations, with a maximum daily dose of 800 mg. For many common intestinal infections, the use pattern involves a 400 mg single dose.

Administration Conditions

Timing with Food: The condition of administration in relation to meals varies by the therapeutic objective. For systemic treatments requiring high tissue concentrations, Captiva is taken with a meal, often specified as a fatty meal, to increase drug absorption. Conversely, for infections localized to the intestinal lumen, administration on an empty stomach may be specified to maximize the local concentration of the drug.

Form Modification: The oral tablets may be crushed or chewed and swallowed with a drink of water, providing flexibility for patients who have difficulty swallowing the tablet whole.

Treatment Duration and Cycles

The total duration of use varies widely. Treatment for neurocysticercosis is typically a continuous course lasting 8 to 30 days. For hydatid disease, the medicine is administered in 28-day treatment cycles followed by a 14-day drug-free interval, a protocol repeated for a total of three cycles. Dosing rules for pediatric and adult patients are often linked to body weight, and while renal adjustment is not expected, hepatic function requires evaluation.

Research Evidence / Overview of Studies

Core Clinical Trials for Low Back Pain

Research has examined whether the compound may have a role for treating acute and chronic low back pain. The primary focus of clinical trials has been to explore changes in patient-reported pain intensity and functional impairment scores.

---

Changes in Reported Pain and Function

Some studies noted that participants reported changes within the first week; however, research exploring whether changes in reported pain are maintained typically focused on treatment periods of four to six weeks.

• Changes in Reported Pain: Studies have evaluated whether the compound's effect is associated with changes in reported pain and muscle stiffness. These studies typically use standard scales like the Visual Analogue Scale (VAS).
• Changes in Function and Mobility: Research has examined whether this combination is associated with changed patient-reported mobility and quality of life, although findings across different trials have been varied.

---

Combination Therapies and Adjunctive Use

A significant portion of the research has focused on studying the compound as an adjunctive strategy alongside physical therapy or other pain management approaches. These studies explore the hypothesis that combined approaches may be associated with differing overall outcomes compared to monotherapy.

---

Population and Context

• Patient Group: The primary evidence has been used to explore whether this treatment may have a role for individuals whose condition has not changed following first-line approaches, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
• Adverse Event Profile: Adverse event reporting across trials indicated that observed adverse events were generally mild. Observed adverse events included reports of gastrointestinal upset and headache.
• Suitability: Determining suitability requires consulting a healthcare professional to review potential risks. It is not yet clear whether specific patient subgroups (e.g., age, underlying pathology) respond differently to the treatment.

Common questions about Captiva (FAQ)

---

Q: Why do doctors prescribe Captiva for so many different conditions?

Official regulatory classifications describe Captiva as a broad-spectrum antihelminthic agent. This means it is used to manage a wide variety of infections caused by different types of parasitic worms. Its inclusion on the World Health Organization (WHO) List of Essential Medicines further underscores its importance in public health for managing parasitic conditions globally.

Q: Is Captiva considered safe to use during pregnancy?

Official documents strictly state that this medicine is contraindicated, or prohibited, for use during pregnancy. This is due to the potential for the medicine to cause fetal harm (known as embryo-fetal toxicity). For females who are of reproductive potential, regulatory guidelines require a negative pregnancy test before treatment. The need for effective contraception during and after treatment is also addressed in regulatory guidelines.

Q: Is there an age limit for taking Captiva?

Regulatory information indicates that Captiva is generally approved for use in individuals over two years of age for short-term courses of therapy. Official documents do not typically specify an upper age limit. Use in all populations is ultimately determined by a healthcare professional based on the specific infection and the patient's overall health status.

Q: What are the most reported side effects of Captiva?

Official documentation of adverse events indicates that commonly reported reactions include temporary elevations of hepatic enzymes (measured by liver tests), headache, abdominal pain, nausea, vomiting, and dizziness/vertigo. These are typically observed in data collected from clinical trials for systemic indications.

Q: Should I avoid grapefruit juice when taking Captiva?

Official drug interaction information notes that Grapefruit juice is documented to increase the plasma levels of the medicine’s active form in the body. This increase in systemic exposure may be a factor in treatment outcomes. The decision regarding dietary changes while taking this medicine is determined by a healthcare professional.

Q: Does Captiva require special monitoring or blood tests?

Yes, regulatory labeling mandates the monitoring of blood counts and liver enzymes at specified intervals throughout the course of treatment. This required monitoring is put in place due to the potential for serious effects on the blood system and the liver.

Q: Are there specific warnings for operating heavy machinery while taking Captiva?

The medicine's safety profile lists adverse reactions that may affect cognitive and motor function, such as dizziness/vertigo and headache. While official documents do not provide direct advice, the potential presence of these effects suggests that caution is warranted before operating heavy machinery or driving.

Q: Can Captiva be taken long-term?

Regulatory documents define specific treatment durations for various indications, ranging from a single dose to continuous courses of up to 30 days or repetitive 28-day cycles. Treatment protocols beyond these defined durations are not addressed in the official product labeling. The length of time the medicine is used depends on the specific parasitic infection being treated.

Q: Can elderly people safely use Captiva?

Regulatory documents do not typically note a specific dose adjustment for the elderly population, which falls under the general adult dosing guidelines. However, labeling mandates caution and close monitoring for underlying conditions that may be more prevalent in older adults, such as hepatic impairment. This is due to the potential for increased risk of adverse effects related to the liver and blood counts.

Q: Can people with kidney problems take Captiva?

Official product information indicates that a dose adjustment is not expected to be necessary for patients with renal impairment (kidney problems). Decisions regarding the appropriateness of this medicine for any patient, including those with pre-existing conditions, are made by a healthcare professional.

Q: Are the side effects of Captiva permanent?

The adverse event profile explicitly notes that alopecia (hair loss) is described as reversible. There is no general statement in official labeling regarding the permanency or duration of all other reported side effects. The specific duration of most side effects is not formally specified in official labeling.

Q: Is it normal to feel dizzy when first starting Captiva?

Official labeling lists dizziness/vertigo as a commonly documented adverse reaction. While the documents do not specify if this effect is concentrated during the first few days of treatment, it is a known possible reaction. Consultation with a healthcare professional is necessary if a patient experiences severe or persistent dizziness.

Q: Is it true that Captiva can interact with certain foods?

Official product information indicates the medicine has specific requirements regarding administration with food. For systemic indications, official documents mandate that the medicine must be taken with a fatty meal to significantly increase the amount absorbed into the body. Separately, Grapefruit juice is documented to increase the active drug levels in the bloodstream.

Q: How long does Captiva stay in your system after stopping it?

Regulatory data indicates that the active metabolite of the drug, Albendazole sulfoxide, has an average elimination half-life of approximately 8.5 hours in plasma. The half-life refers to the time it takes for the concentration of the substance to be reduced by half in the body.

Q: Where can I find the official regulatory documents for Captiva?

Official drug product information, such as the U.S. Prescribing Information or the European Summary of Product Characteristics (SmPC), can be found on the websites of national regulatory bodies. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Q: Why was Captiva approved by the FDA?

The approval of Captiva reflects its established efficacy in treating parasitic conditions, as documented by regulatory bodies. Its importance is further underscored by its inclusion on the World Health Organization (WHO) List of Essential Medicines, which confirms its established role in public health for managing various parasitic conditions globally.

Q: What is the difference between an allergy and a side effect of Captiva?

Hypersensitivity (an allergic reaction) to Captiva or its components is a formal contraindication, meaning the medicine must not be used. A side effect (or adverse reaction) is a commonly or less commonly documented unfavorable reaction that may occur during use.

Q: Is Captiva a controlled substance?

According to regulatory authorities, the drug is classified as a non-scheduled prescription medicine. It is not listed under the U.S. Controlled Substances Act and is not associated with potential for abuse.

Q: Does Captiva affect fertility?

Official product labeling strictly mandates contraception for women of childbearing potential due to the potential risk of embryo-fetal toxicity. However, there is no explicit statement in the labeling regarding general effects on either male or female fertility.

Q: Are there any known issues with taking Captiva while traveling?

Official storage guidelines state that the medicine must be stored at controlled room temperature (between 20°C and 25°C or 68°F and 77°F) and must not be frozen. These temperature constraints are key factors in maintaining product integrity during transport.

Q: Why is Captiva sometimes prescribed for a short time only?

The drug is prescribed for short courses because its approved treatment durations for various parasitic infections are fixed, ranging from a single dose up to a defined continuous course of 30 days. The length of therapy is determined by the specific type and location of the infection being addressed.

Q: Does Captiva carry a Black Box Warning?

Official labeling for the medicine does not contain a Black Box Warning (also known as a Boxed Warning) from the U.S. Food and Drug Administration (FDA). However, the label does include prominent warnings regarding the potential for serious effects like bone marrow suppression and hepatotoxicity (liver damage).

Q: Are there foods that can make Captiva less effective?

For systemic treatment, official documents mandate that the medicine be taken with a fatty meal in order to maximize its absorption into the body. Administration without a fatty meal may result in lower overall systemic exposure.

Q: Does Captiva affect vision?

Official labeling requires an ophthalmologic examination (eye exam) before starting treatment for neurocysticercosis, a specific type of parasitic infection, to rule out retinal lesions. General adverse visual effects are not listed as common reactions.

Q: What happens if Captiva is taken past its expiration date?

Regulatory rules mandate that expired medication be safely discarded. Disposal should follow official guidelines, such as utilizing a drug take-back program or adhering to specific local environmental requirements for pharmaceutical waste.

Q: Is Captiva habit-forming or addictive?

The drug is classified as a non-scheduled prescription medicine and is not associated with abuse liability. According to regulatory documents, the medicine is not considered habit-forming or addictive.

Storage and Disposal Requirements (Albendazole)

The storage of Albendazole, the active ingredient in Captiva, must adhere strictly to controlled conditions defined by regulatory documents to maintain product integrity.

Storage Requirement	Condition
Temperature	Store at controlled room temperature, between 20°C and 25°C (68°F and 77°F).
Environmental Protection	Keep away from excess heat, moisture, and direct light. It is mandatory to keep the product from freezing.
Container Integrity	The medication must be kept in the original container, which must be kept tightly closed.

For safety, the product must be stored locked up and strictly out of the sight and reach of children. Unused or expired Albendazole must be discarded. Disposal should follow official guidelines, such as utilizing a drug take-back program or adhering to specific local environmental requirements for pharmaceutical waste.